Purple Biotech: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Purple Biotech (NASDAQ:PPBT) reported Q3 earnings with an EPS of $-0.23, which was in line with estimates. Revenue was unchanged from the same period last year. The company's past earnings performance showed a slight beat on EPS but was followed by a 2.44% drop in share price the next day.
November 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Purple Biotech reported Q3 earnings with an EPS of $-0.23, in line with estimates, and no change in revenue from the same period last year.
Purple Biotech's earnings report showed an EPS that met analyst expectations and no revenue growth. Historically, a similar earnings performance resulted in a slight drop in share price. However, since the results were as expected, the short-term impact is likely to be neutral, barring any unforeseen market reactions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100